A PROSPECTIVE LOW-INTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK® IN RECURRENT OR METASTATIC CERVICAL CANCER
Latest Information Update: 19 Feb 2026
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Sponsors Pfizer
Most Recent Events
- 25 May 2025 Status changed from not yet recruiting to recruiting.
- 09 May 2025 New trial record